01 Meningococcal Poehling 508
Document text
ACIP Meningococcal Vaccines Work Group Introduction Katherine Poehling, MD, MPH Chair, ACIP Meningococcal Vaccines Work Group October 25, 2023National Center for Immunization & Respiratory Diseases Meningococcal Vaccines Work Group ▪ ACIP Members on the WG •Katherine Poehling (Chair) •Lynn Bahta •Jamie Loehr ▪ Ex Officio WG Members •Margaret Bash (FDA) •Mark Connelly (FDA) •Francisco Leyva (NIH) ▪ WG Liaisons and Consultants •Amra Resic (AAFP) •Samir Shah (AAP) •Sharon McMullen (ACHA) •Cacky Tate / Karyn Lyons (AIM) •Paul Cieslak (CSTE) •Kathy Hsu (IDSA) •Joseline Zafack (NACI) •Jeff Goad (NFID) •Jessica Cataldi (PIDS) •Amy Middleman (SAHM) •David Stephens (Emory)▪ CDC Contributors •Jennifer Collins (DBD/NCIRD) •Sam Crowe (DBD/NCIRD) •Lucy McNamara (DBD/NCIRD) •Ismael Ortega -Sanchez (DVD/NCIRD) •Andrew Leidner (ISD/NCIRD) •LeAnne Fox (DBD/NCIRD) •Susan Hariri (DBD/NCIRD) •Amy Rubis (DBD/NCIRD) •Noele Nelson (DBD/NCIRD) •Alison Albert (DBD/NCIRD) •Angela Jiles (DBD/NCIRD) •Jonathan Duffy (DHQP/NCEZID) •Tanya Myers (DHQP/NCEZID) •Liz Velazquez (ISD/NCIRD) •Jessica MacNeil (ACIP Secretariat) •Melinda Wharton (ACIP Secretariat) ▪ GRADE/EtR Support •Doug Campos -Outcalt (Arizona) •Rebecca Morgan (Case Western Reserve) 2 Policy topics under consideration by Work Group regarding Pfizer’s pentavalent vaccine ▪Should pentavalent vaccine be included as an option for MenACWY /MenB vaccination in people currently recommended to receive both vaccines ? ▪Should pentavalent vaccine be included as an option for people currently recommended to receive MenACWY only ? ▪Should pentavalent vaccine be included as an option for people currently recommended to receive MenB only ? 3 Summary of ACIP meetings ▪February 2023 –Epidemiology of meningococcal disease in the United States –Pfizer’s MenABCWY vaccine clinical trials data –Work group interpretation of Pfizer’s MenABCWY trials data ▪June 2023 –CDC’s cost effectiveness model –Summary of GRADE and EtRframework 4 Meningococcal Work Group Meeting Review June─October 2023 ▪Feedback from June ACIP meeting –Review of meningococcal schedule postponed to allow for consideration of GSK’s forthcoming pentavalent vaccine and availability of data about post -COVID meningococcal epidemiology ▪Comparisons of cost -effectiveness models ▪Updates on CDC cost -effectiveness model with new price estimate –Price for pentavalent was ~$40 –90 more than MenB and now is similar ▪Discussed 3 potential recommendation options based on concerns raised by ACIP members in June and new cost -effectiveness estimates 5 Work Group determinations for policy questions ▪Should the pentavalent vaccine be included as an option for MenACWY /MenB vaccination in people currently recommended to receive both vaccines ? •YES (strong consensus) ▪Should the pentavalent vaccine be included as an option for people currently recommended to receive MenACWY only ? •NO (strong consensus) ▪Should the pentavalent vaccine be included as an option for people currently recommended to receive MenB only ? •Perhaps (limited consensus) 6 Today’s agenda ▪Meningococcal Vaccines Session ▪Later today –Meningococcal vote regarding Pfizer’s MenABCWY vaccine –Meningococcal VFC vote regarding Pfizer’s MenABCWY vaccine 7Topic Presenter Plan for revisiting the adolescent schedule for meningococcal vaccines Dr. Lucy McNamara (CDC/NCIRD) Comparison of Pfizer and CDC cost effectiveness analyses for Pfizer’s MenABCWY vaccineDr. Ismael Ortega -Sanchez (CDC/NCIRD) Summary of EtRand proposed recommendations for Pfizer’s MenABCWY vaccineDr. Jennifer Collins (CDC/NCIRD) Vaccines for Children Resolution Dr. Jeanne Santoli (CDC/NCIRD)